Table 3 Clinical data for the study population (n = 49) at baseline, 15, and 30 weeks.
| Â | Baseline median (range) | 15 weeks median (range) | 15-0 weeks difference median (range) | Pvalue | 30 weeks median (range) | 30 to 0 weeks difference median (range) | Pvalue |
|---|---|---|---|---|---|---|---|
Pain threshold kPa | 202.8 (105.9-380.5) | 189.9 (112.2-305.3) | -9.6 (-102.1-75.6) | 0.040 | 194.3 (107.6-472.3) | -8.8 (-165.2-108.5) | 0.608 |
Pain 0 to 100 | 71 (7-98) | 65.5 (3-99) | -5 (-40-35) | 0.052 | 67 (14-95) | -2 (-39-53) | 0.365 |
6MWT m | 518 (381-660) | 566 (418-689 | 25.1 (-77-164.5) | < 0.001 | 555 (367.5-661) | 15.5 (-150.5-145) | 0.009 |
IGF-1 ng/ml | 4.2 (0-35.7) | 3.0 (0-33.8) | -0.2 (-31.6-28.7) | 0.085 | 2.7 (0-10.9) | -0.7 (-31.2-1.7) | 0.004 |
IGFB3 ng/ml | 1,549.4 (2,69.5-3,288.3) | 1,634 (182.4-2,967.3) | -57.5 (-1,551.7-1,846.6) | 0.889 | 1,795.4 (98.3-4,156.7) | 272.9 (-1,563-2,821.8) | 0.413 |